|
Study of T900607-sodium in previously treated patients with ovarian cancer. Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Study of T900607-sodium in previously treated patients with ovarian cancer. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of T900607-sodium in previously treated patients with ovarian cancer. Clinical research trials and Study of T900607-sodium in previously treated patients with ovarian cancer. health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Study of T900607-sodium in previously treated patients with ovarian cancer.. Study of T900607-sodium in previously treated patients with ovarian cancer. Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Study of T900607-sodium in previously treated patients with ovarian cancer. clinical trial. Human subjects often get the best healthcare possible for their Study of T900607-sodium in previously treated patients with ovarian cancer. condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of T900607-sodium in previously treated patients with ovarian cancer.  Study of T900607-sodium in previously treated patients with ovarian cancer.
Study of T900607-sodium in previously treated patients with ovarian cancer.
For Condition: Ovarian Neoplasms
Status: No longer recruiting
Sponsor(s): Tularik ,
Synopsis: The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - Histologically or cytologically confirmed diagnosis of ovarian cancer - Subjects must have received 1-2 regimens of prior chemotherapy (with one containing paclitaxel) - At least 18 years of age - Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size. - Karnofsky performance status of at least 70% - Estimated life expectancy of at least 12 weeks - Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive - Subject must be able to comply with study procedures and follow-up examinations. - Signed written informed consent - Lab Values (obtained 7 days prior to study enrollment): * ANC at least 1.5x10e9/L, * Platelet count at least 100x10e9/L, * Hemoglobin at least 8.5 g/dL, * Creatinine within 2 times upper limit of normal * AST and ALT within 3 times upper limit of normal * Bilirubin within 1.5 times upper limit of normal * Albumin great than 2.5 g/dL * INR < 1.5 for subjects without anticoagulants Exclusion Criteria - Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment - NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%, or acute anginal symptoms - Patients who have received any investigational agent within 4 weeks of enrollment - Patients who are pregnant or breast-feeding - History of prior malignancy other than ovarian cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - History of central nervous system metastases or carcinomatous meningitis - Major surgery within 4 weeks of enrollment
Total Enrollment: 35
Location and Contact Information:
Overall Study Official:
KerrieBoyd, Study Chair, Tularik
University of California San Francisco
San Francisco, California, 94115
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
USC Women's and Children's Hospital
Los Angeles, California, 90033
United States
Scripps Health Center
La Jolla, California, 92037
United States
Roswell Park Cancer Center
Buffalo, New York, 14263
United States
Additional Information:
Study ID Numbers: T-607-005;
Study Start Date: July 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00043446
Other Ovarian Neoplasms Studies:
1. Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
2. Study of T900607-sodium in previously treated patients with ovarian cancer.
3. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
4. Removal of the ovaries/fallopian tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
5. Tariquidar and Docetaxel to Treat Patients with Lung, Ovarian, and Cervical Cancer
Related Studies:
Other Ovarian Neoplasms Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Study of T900607-sodium in previously treated patients with ovarian cancer.
|
|
|
|
|
|
|
|
